title: Identification of restriction endonuclease with potential ability to cleave the HSV-2 genome: inherent potential for biosynthetic versus live recombinant microbicides.
abstract: BACKGROUND
  Herpes Simplex virus types 1 and 2 are enveloped viruses with a linear dsDNA genome of approximately 120-200 kb. Genital infection with HSV-2 has been denoted as a major risk factor for acquisition and transmission of HIV-1. Developing biomedical strategies for HSV-2 prevention is thus a central strategy in reducing global HIV-1 prevalence. This paper details the protocol for the isolation of restriction endunucleases (REases) with potent activity against the HSV-2 genome and models two biomedical interventions for preventing HSV-2.
  
  
  RESULTS
  Using the whole genome of HSV-2, 289 REases and the bioinformatics software Webcutter2; we searched for potential recognition sites by way of genome wide palindromics. REase application in HSV-2 biomedical therapy was modeled concomitantly. Of the 289 enzymes analyzed; 77(26.6%) had potential to cleave the HSV-2 genome in > 100 but < 400 sites; 69(23.9%) in > 400 but < 700 sites; and the 9(3.1%) enzymes: BmyI, Bsp1286I, Bst2UI, BstNI, BstOI, EcoRII, HgaI, MvaI, and SduI cleaved in more than 700 sites. But for the 4: PacI, PmeI, SmiI, SwaI that had no sign of activity on HSV-2 genomic DNA, all 130(45%) other enzymes cleaved < 100 times. In silico palindromics has a PPV of 99.5% for in situ REase activity (2) Two models detailing how the REase EcoRII may be applied in developing interventions against HSV-2 are presented: a nanoparticle for microbicide development and a "recombinant lactobacillus" expressing cell wall anchored receptor (truncated nectin-1) for HSV-2 plus EcoRII.
  
  
  CONCLUSIONS
  Viral genome slicing by way of these bacterially- derived R-M enzymatic peptides may have therapeutic potential in HSV-2 infection; a cofactor for HIV-1 acquisition and transmission.
authors.affiliation: Restrizymes Biotherapeutics Uganda Limited, Kampala, Uganda. wmisaki@yahoo.com
authors.forename: Misaki
authors.initials: M
authors.lastname: Wayengera
authors.forename: Henry
authors.initials: H
authors.lastname: Kajumbula
authors.forename: Wilson
authors.initials: W
authors.lastname: Byarugaba
mesh_terms: D000890:Anti-Infective Agents / Q000138:chemical synthesis / Q000378:metabolism; D035843:Biomedical Research / Q000379:methods; D004262:DNA Restriction Enzymes / Q000378:metabolism*; D015252:Deoxyribonucleases, Type II Site-Specific / Q000378:metabolism; D016679:Genome, Viral / Q000235:genetics*; D015658:HIV Infections / Q000517:prevention & control; D018258:Herpesvirus 2, Human / Q000235:genetics*; D006801:Humans; D010446:Peptide Fragments / Q000008:administration & dosage / Q000627:therapeutic use; D014764:Viral Proteins / Q000378:metabolism
chemical_list: D000890:Anti-Infective Agents; D010446:Peptide Fragments; D014764:Viral Proteins; D004262:DNA Restriction Enzymes; C046545:CCWGG-specific type II deoxyribonucleases; D015252:Deoxyribonucleases, Type II Site-Specific